Takeda Pharmaceutical (TAK) said Wednesday that it has appointed Julie Kim as president and chief executive officer.
Kim succeeds Christophe Weber, who retired from both the company and its board following the annual meeting of shareholders.
Kim joined Takeda in 2019 and was named CEO-elect in 2025, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments